Hims & Hers Acquires Eucalyptus for $1.6B, Minting 100 Aussie Millionaires
US telehealth giant Hims & Hers has acquired Sydney-based startup Eucalyptus in a landmark $1.6 billion deal. The acquisition, fueled by a $637 million revenue run-rate and the global GLP-1 weight loss boom, has created over 100 overnight millionaires among the Australian firm's staff.
Beat this week
Last 7 days · Acquisitions
Impact 6.0/10 (-0.2 vs prior). Counts are stories in our record, not a market forecast.
Open the change reportCoverage balance Positive coverage leads. Positive coverage exceeds negative coverage by 100 percentage points.
This story sits in Acquisitions — the counts compare this beat's last 7 days with the previous 7 in our verified record, not a market forecast.
Figures are computed live from our source-verified story record (as of ) The volume change compares this window with the prior 7 days in the same record. — see our methodology for how impact and sentiment are derived.
Startup briefing
Key takeaways
- US telehealth giant Hims & Hers has acquired Sydney-based startup Eucalyptus in a landmark $1.6 billion deal.
- The acquisition, fueled by a $637 million revenue run-rate and the global GLP-1 weight loss boom, has created over 100 overnight millionaires among the Australian firm's staff.
In this briefing
Mentioned
Key Intelligence
Key Facts
- 1Hims & Hers acquired Eucalyptus for a total deal value of $1.6 billion
- 2Eucalyptus reported an annual revenue run-rate exceeding $637 million at the time of sale
- 3Over 100 employees became millionaires through a $300 million share option pool
- 4Founder Tim Doyle is set to receive $163 million from the acquisition
- 5The average employee payout from the share plan is estimated at $420,000
- 6Eucalyptus brands Juniper and Pilot specialize in GLP-1 weight loss and men's health
Who's Affected
Analysis
The acquisition of Eucalyptus by Hims & Hers for $1.6 billion represents a watershed moment for the Australian technology ecosystem, signaling the maturity of the region's direct-to-consumer healthcare sector. Eucalyptus, the parent company behind prominent brands like Juniper and Pilot, has rapidly scaled by leveraging the surging global demand for GLP-1 medications, such as those similar to Ozempic and Mounjaro. By integrating Eucalyptus into its global portfolio, Hims & Hers is not merely buying market share in the Asia-Pacific region; it is acquiring a proven operational mirror of its own successful US model, which Eucalyptus founder Tim Doyle admits was the original inspiration for the company.
Eucalyptus managed to build a formidable revenue engine, reaching an annual run-rate exceeding $637 million prior to the sale. This growth was driven by a sophisticated multi-brand strategy: Juniper targets women’s health and weight management, while Pilot focuses on men’s health, including erectile dysfunction and hair loss. The company’s ability to navigate the complex regulatory environment of telehealth prescriptions in Australia while maintaining high growth made it an irresistible target for Hims & Hers, which is currently in an aggressive phase of international expansion to maintain its dominance in the personalized health space.
The acquisition of Eucalyptus by Hims & Hers for $1.6 billion represents a watershed moment for the Australian technology ecosystem, signaling the maturity of the region's direct-to-consumer healthcare sector.
The financial implications for the Sydney tech scene are profound. The deal includes a $300 million share pool for employees, excluding the co-founders, which has effectively minted over 100 millionaires overnight. With an average payout of approximately $420,000 per employee, this liquidity event is expected to trigger a 'wealth effect' within the local ecosystem. We are likely to see the emergence of a 'Eucalyptus Mafia,' similar to the early alumni of PayPal or Canva, where former employees use their windfalls to seed a new generation of Australian startups. Former Chief Commercial Officer Joe Harris has already signaled this intent, noting that his seven-figure payout allows him to focus entirely on building his next venture without the burden of opportunity cost.
What to Watch
For Hims & Hers, the acquisition is a strategic masterstroke but one that comes with inherent risks. The telehealth GLP-1 market is under increasing scrutiny from global health regulators concerned about the long-term safety and prescription protocols of weight-loss drugs. By doubling down on this category through Eucalyptus, Hims & Hers is betting that the shift toward digital-first chronic condition management is permanent. The integration will likely focus on harmonizing supply chains for compounded medications and expanding the Eucalyptus brands into new geographic territories under the Hims & Hers umbrella.
Looking forward, this deal sets a new valuation benchmark for telehealth startups globally. It demonstrates that companies capable of combining high-margin pharmaceutical sales with a recurring subscription model can command massive premiums, even in a high-interest-rate environment. Investors will be watching closely to see if other US-based health giants follow suit by acquiring regional leaders in Europe and South America to build truly global digital health platforms. For now, the focus remains on Sydney, where the successful exit of Eucalyptus serves as a powerful validation of the Australian venture capital model and its ability to produce world-class health-tech contenders.
Timeline
Timeline
Eucalyptus Founded
Tim Doyle launches the company, inspired by the Hims & Hers telehealth model in the US.
GLP-1 Surge
Juniper and Pilot brands see explosive growth driven by demand for weight-loss medications.
Acquisition Announced
Hims & Hers officially announces the $1.6 billion deal to acquire Eucalyptus.
Employee Windfall
Details of the $300M employee share pool emerge, confirming 100+ new millionaires.
Cite This Page
"Hims & Hers Acquires Eucalyptus for $1.6B, Minting 100 Aussie Millionaires." Startup Intelligence Brief, February 24, 2026. https://getstartupbrief.com/story/hims-and-hers-eucalyptus-acquisition-analysis
How we covered this story
Every story in our startup coverage is assembled from multiple primary sources, cross-referenced for factual consistency, and scored along three independent dimensions: sentiment, operational impact, and source-cluster confidence. Single-source rumors and unverifiable claims do not pass our editorial gate. When a story shows "Verified by N sources" with N≥2, the development is independently corroborated; when N=1, we mark it explicitly so readers can weigh the signal accordingly.
Impact scoring uses a 1-10 scale weighted toward regulatory, financial, and operational consequence rather than coverage volume. A topic that runs in every outlet but moves no real decisions ranks lower than a niche regulatory filing that reshapes how operators in the startup space have to behave. Read our full methodology for the scoring rubric, our glossary for term definitions, and our trends index for the longitudinal view across the beat.
Sources are only linked to a story once they clear our classification pipeline at a minimum 35 percent relevance threshold. According to that methodology, reviewed July 2026, this follows multi-source corroboration standards recommended by journalism research bodies such as the Reuters Institute for the Study of Journalism.
See something wrong in this story — a wrong fact, a broken source link, a misattributed entity? Report a data issue.
| Signal on this page | What it tells you |
|---|---|
| Verified by N sources | Independent corroboration count. N≥2 is our confidence floor; N=1 is marked explicitly. |
| Impact score (1-10) | Regulatory + financial + operational weight. 8+ signals an experienced-operator action item. |
| Sentiment | Five-tier classification trained on labeled startup-specific corpora. |
| Timeline | Where applicable, the related-events sequence that contextualizes today's development. |